FECD-TRACE: Fuchs' Endothelial Corneal Dystrophy TRAjectory and Correlation With Genotype in the United Kingdom
Launched by UNIVERSITY COLLEGE, LONDON · Mar 11, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The FECD-TRACE trial is a research study focused on understanding Fuchs' Endothelial Corneal Dystrophy (FECD), a condition that affects the cornea, the clear front part of the eye. This study aims to follow a group of younger individuals who may be genetically more likely to develop FECD over several years. Researchers will use advanced imaging techniques to observe changes in the cornea and will also look at genetic information to see how it relates to the progression of the disease. The ultimate goal is to improve our understanding of FECD and help create personalized treatment options for those affected.
To participate in this study, individuals must be willing to give consent and attend regular study visits, which will include clinical examinations and providing blood or saliva samples. Participants should not have other eye conditions that could complicate the study, nor have had recent eye surgeries, as these factors could interfere with the research. This trial is currently recruiting participants aged 65 to 74, and both men and women are welcome to join. If you're interested in learning more or think you might qualify, don’t hesitate to reach out for more information!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Willing and able to provide informed consent for participation in the study
- • Willing to attend scheduled study visits and undergo a clinical examination
- • Willing to donate blood/saliva samples
- • Fulfil the abovementioned cohort criteria
- Exclusion Criteria:
- • Presence of a secondary cause for corneal endothelial dysfunction or oedema
- • Presence of clinically evident corneal oedema
- • History of concurrent corneal diseases
- • History of corneal surgeries, including corneal transplantation
- • Cognitive impairment or inability to provide informed consent for participation in the study
About University College, London
University College London (UCL) is a leading global research institution renowned for its commitment to advancing healthcare through innovative clinical trials. As a prominent sponsor of clinical research, UCL leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and addressing pressing medical challenges. The institution fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring that its trials adhere to the highest ethical standards and regulatory guidelines. UCL's dedication to translating scientific discoveries into practical applications underscores its role as a vital contributor to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Alice Davidson, PhD
Principal Investigator
University College, London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported